STOCK TITAN

Oncotelic Therapeutics Inc - OTLC STOCK NEWS

Welcome to our dedicated news page for Oncotelic Therapeutics (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oncotelic Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oncotelic Therapeutics's position in the market.

Rhea-AI Summary
Oncotelic Therapeutics, Inc (OTCQB:OTLC) announces a groundbreaking peer-reviewed publication on the therapeutic targeting of negative prognostic markers in low-grade gliomas. The study reveals the crosstalk between TGF-β and IFN signaling pathways, offering new strategies for treating gliomas and Systemic Lupus Erythematosus (SLE). The research identifies IRF5 as a common target for both diseases, potentially revolutionizing cancer treatment by modulating the immune response. Detailed analysis shows that low mRNA levels of TGFB2 and IFNGR2 result in improved survival for LGG patients, highlighting potential therapeutic targets for high-risk patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Oncotelic Therapeutics, Inc (OTLC) announces the initiation of the STOP-PC clinical trial for advanced pancreatic cancer. The trial focuses on OT-101, a novel RNA therapeutic targeting TGF-β2 to enhance immune response and inhibit tumor growth. Notably, OT-101 has shown promising single-agent activity with dose-dependent survival benefits. The Phase 2/3 trial will evaluate OT-101 in combination with mFOLFIRINOX compared to mFOLFIRINOX alone as second-line therapy for progressing cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.89%
Tags
conferences clinical trial
-
Rhea-AI Summary
Oncotelic Therapeutics, Inc announced the publication of a study on the impact of TGFB2 and IFNGR2 mRNA levels in pediatric DMG patients. The study reveals that elevated TGFB2 levels worsen mortality in DMG patients and highlights the potential of IFNGR2 in enhancing immune surveillance for cancer immunotherapy. The findings suggest that targeting TGFB2 and IFNGR2 could lead to improved overall survival outcomes for pbDMG patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Oncotelic Therapeutics, Inc (OTCQB:OTLC) unveils a state-of-the-art GMP Manufacturing Plant in a joint venture with Sapu Biosciences LLC, marking a significant stride in biopharmaceutical innovation and a pivotal expansion in the company's clinical pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced its CEO, Dr. Vuong Trieu, will be a featured speaker at the Ibero-American Chatbot and Conversational AI Summit. He will discuss the Company’s proprietary chatbots, part of the Orion AI Technology suite, at the November 29th and 30th, 2023 summit. The chatbots aim to overcome traditional AI communication challenges and have multilingual capabilities, advancing global participation in biotechnological innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary
Oncotelic Therapeutics, Inc. (OTCQB:OTLC) announced financial results for Q3 2023, showing unchanged R&D costs, significantly lower G&A costs, and reduced net loss and operating expenses. The company is benefitting from a joint venture with Dragon Overseas Limited, which has absorbed most R&D and G&A expenditures related to OT-101, allowing the company to continue development efforts at no cash cost. Plans for an initial public offering of the joint venture in Hong Kong or another exchange are in progress, and the company aims to accelerate clinical programs in multiple indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Oncotelic Therapeutics featured in Life Sciences Review and awarded Top Cancer Immunotherapy Solutions Provider 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.33%
Tags
none
-
Rhea-AI Summary
Oncotelic announces joint venture for registrational trial in pancreatic cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Oncotelic Therapeutics Inc

OTC:OTLC

OTLC Rankings

OTLC Stock Data

16.37M
179.76M
54.9%
2.5%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Agoura Hills